drugset / Trial / NCT01801280

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

NCT01801280 ↗

Phase 4 Completed 20 enrolled Klemens Budde Novartis Pharmaceuticals · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this pharmacokinetic study is to examine a possible drug-drug interaction of Pantoprazole on the bioavailability mycophenolic acid.

Timeline

Start
2012-01
Primary completion
2013-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 1000 mg —
Subject Mycophenolate Mofetil Small molecule 1500 mg —
Subject Mycophenolate Mofetil Small molecule 2000 mg —
Subject Mycophenolate Sodium Unknown 720 mg —
Subject Mycophenolate Sodium Unknown 1080 mg —
Subject Mycophenolate Sodium Unknown 1440 mg —
Subject Pantoprazole Other / unclassified 40 mg —